Ajanta Pharma approves financial statements at AGM

Ajanta Pharma Ltd held its 47th Annual General Meeting (AGM) on July 16, 2026, through video conferencing, approving all four resolutions listed on the agenda. The meeting saw the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Shareholders also confirmed the interim dividend for the financial year ended March 31, 2026.

Pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted the voting results and the Consolidated Scrutinizer's Report. The remote e-voting process was conducted via the NSDL platform from July 13, 2026, to July 15, 2026, for shareholders holding shares as on the record date of July 9, 2026.

Voting Results Summary

The resolutions were passed with the requisite majority. The table below details the voting outcomes for each resolution:

Resolution Description	Votes For	Votes Against	% For	% Against
Adoption of Financial Statements FY26	111,336,195	5,305	99.9952	0.0048
Confirmation of Interim Dividend FY26	111,447,501	918	99.9992	0.0008
Reappointment of Director Mr. Mannalal Bhagwandas Agrawal	109,994,994	1,439,762	98.7080	1.2920
Ratification of Cost Auditors Remuneration FY27	111,433,629	1,112	99.9990	0.0010

Key Resolutions

Financial Statements and Dividend

The first ordinary resolution sought the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors. The second resolution confirmed the interim dividend for the financial year ended March 31, 2026.

Director Reappointment

A special resolution was passed to appoint a director in place of Mr. Mannalal Bhagwandas Agrawal (DIN: 00073828), who retires by rotation and offered himself for reappointment. This resolution received 98.7080% votes in favour.

Cost Auditor Ratification

The final ordinary resolution concerned the ratification of the remuneration of cost auditors for the financial year 2026-2027. This resolution was approved with 99.9990% of votes in favour. The scrutinizer for the e-voting process was Pramod S. Shah of Pramod S. Shah & Associates, Practising Company Secretaries.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.97%	+3.38%	+11.03%	+27.55%	+22.66%	+137.98%

Promoter Ravi Agrawal released the pledge on 2,600 equity shares of ajanta pharma due to excess pledge, reducing the encumbered holding of the Ravi Agrawal Trust to 1,535,096 shares. The release, which occurred on July 9, 2026, was disclosed to the stock exchanges on July 13, 2026, under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The shares were previously pledged with HSBC Direct Invest Financial Services Pvt Ltd, with the depository participant being Barclays Securities (India) Private Limited. Following the release, the encumbered holding represents 1.23% of the total share capital of the company. The disclosure was submitted by Ravi Purushottam Agrawal in his capacity as trustee of the Ravi Agrawal Trust.

Shareholding Details

The filing provides a comprehensive overview of the promoter group's shareholding and encumbrance status as of the reporting date. The table below details the holdings of key promoters and the status of their encumbered shares.

Promoter Name	Total Holding	% of Share Capital	Encumbered Shares (Pre-event)	Encumbered Shares (Post-event)	% of Share Capital (Post-event)
Gabs Investments Pvt Ltd	12,588,393	10.08	2,770,000	2,770,000	2.22
Yogesh M Agrawal (Trustee)	18,078,147	14.47	-	-	-
Mannalal B Agrawal	0	0.00	-	-	-
Rajesh M Agrawal (Trustee)	18,078,148	14.47	-	-	-
Ravi P Agrawal (Trustee)	12,792,904	10.24	1,537,696	1,535,096	1.23
Ravi P. Agrawal	285,000	0.23	-	-	-
Aayush M Agrawal (Trustee)	14,112,924	11.30	13,532,924	13,532,924	10.83
Aayush M. Agrawal	30,000	0.02	0	30,000	0.02
Ganga Exports	3,348,261	2.68	-	-	-

The disclosure confirms that the release of pledge was a specific action taken by Ravi Agrawal to adjust the level of encumbrance against his holdings. The filing was addressed to BSE Limited and the National Stock Exchange of India for necessary record-keeping.